Eric Bjerkholt
Eric Bjerkholt's purchase track record
How the stock did after each of Eric Bjerkholt's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/27/2024 | MIRM | $50K | +30.8% | +55.2% | +9.0% |
| 3/18/2024 | MIRM | $52K | +27.0% | +55.6% | +9.4% |
| 12/13/2023 | CERS | $16K | +12.2% | +1.7% | +15.2% |
| 9/11/2023 | MIRM | $296K | +6.1% | -11.5% | +14.1% |
| 8/21/2023 | CERS | $17K | +5.3% | +35.9% | +13.1% |
| 5/30/2023 | CALC | $1K | pending | pending | — |
| 5/23/2023 | CERS | $10K | -11.9% | -12.9% | +9.5% |
| 5/16/2023 | CALC | $6K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Cerus to Present at 2026 AABB Annual Meeting. Cerus Corporation announced it will host a workshop and present abstracts at the upcoming 2026 AABB Annual Meeting. This event highlights the company's ongoing scientific engagement and clinical data sharing within the blood banking community. The announcement serves as a routine corporate update, providing context for the stock's current trading position near its support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
Transaction History
| MIRM | ▼ Sell | Open Market | 9,943 | $978K | 9/14/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 18,333 | — | 9/11/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,001 | $600K | 8/11/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 528 | $65K | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 300 | $37K | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,048 | $128K | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 3,124 | $380K | 7/6/2026 | View on chart |
| CERS | ▼ Sell | Open Market | 20,454 | $53K | 6/9/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,393 | $63K | 6/9/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,258 | $210K | 6/8/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,567 | $149K | 6/8/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,175 | $110K | 6/8/2026 | View on chart |
| CERS | ▲ Buy | Grant | 60,000 | $0 | 6/2/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 7,287 | $670K | 3/16/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 13,334 | — | 3/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,053 | $101K | 1/26/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,667 | — | 1/23/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,421 | $133K | 1/22/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 3,334 | — | 1/21/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 9,578 | $728K | 9/12/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 18,333 | — | 9/11/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,954 | $78K | 8/12/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 8,000 | — | 8/11/2025 | View on chart |
| CERS | ▲ Buy | Grant | 60,000 | $0 | 6/3/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,667 | — | 1/23/2025 | View on chart |
| CERS | ▼ Sell | Open Market | 20,000 | $36K | 12/12/2024 | View on chart |
| MIRM | ▲ Buy | Grant | 475 | $10K | 11/8/2024 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 18,334 | — | 9/11/2024 | View on chart |
| CERS | ▲ Buy | Grant | 40,000 | $200K | 6/5/2024 | View on chart |
| MIRM | ▲ Buy | Grant | 470 | $10K | 5/10/2024 | View on chart |
| MIRM | ▲ Buy | Open Market | 2,000 | $50K | 3/27/2024 | View on chart |
| MIRM | ▲ Buy | Open Market | 2,000 | $52K | 3/18/2024 | View on chart |
| CERS | ▲ Buy | Open Market | 10,000 | $16K | 12/13/2023 | View on chart |
| MIRM | ▲ Buy | Open Market | 10,000 | $296K | 9/11/2023 | View on chart |
| CERS | ▲ Buy | Open Market | 10,000 | $17K | 8/21/2023 | View on chart |
| CERS | ▲ Buy | Grant | 40,000 | $200K | 6/7/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 100 | $409 | 5/31/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 150 | $630 | 5/31/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 5 | $16 | 5/30/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 500 | $2K | 5/23/2023 | View on chart |
| CERS | ▲ Buy | Open Market | 5,000 | $10K | 5/23/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 199 | $527 | 5/19/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1 | $3 | 5/18/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 300 | $810 | 5/18/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 200 | $534 | 5/17/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 800 | $2K | 5/16/2023 | View on chart |
| CALC | ▼ Sell | Other | 1,429 | — | 3/23/2023 | View on chart |
| CERS | ▲ Buy | Grant | 20,454 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.